We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology Newsfeed
  • Blog
  • Events
  • Popular
  • Awards
  • About
  • Login Register
  • Newsfeed
  • GTDT
    • GTDT home
    • Guides
    Getting The Deal Through joins Lexology
    GTDT and Lexology Navigator have merged
  • Hubs
  • Webinars
  • Learn
  • Store
  • Analytics
  • Insights
  • Track
  • Create
  • My Lexology
  • Blog
  • Events
  • Popular
  • Awards
  • About
  • Login Register
  • Newsfeed
  • GTDT
    • GTDT home
    • Guides
    Getting The Deal Through joins Lexology
    GTDT and Lexology Navigator have merged
  • Hubs
  • Webinars
  • Learn
  • Store
  • Analytics
  • Insights
  • Track
  • Create
  • My Lexology
Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Linked In
  • Follow
    Please login to follow content.
  • Like

add to folder:

  • My saved (default)
  • Read later
Folders shared with you

Register now for your free, tailored, daily legal newsfeed service.

Questions? Please contact customerservices@lexology.com

Register

Variations on a theme: five proposed abbreviated approval pathways for biogenerics

Venable LLP

To view this article you need a PDF viewer such as Adobe Reader. Download Adobe Acrobat Reader

USA May 5 2009

In the pharmaceutical context, the term “biologics” generally refers to protein-based medicines that are made in living cells, such as insulin and human growth hormone.

Venable LLP - Christopher E. Loh
Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Linked In
  • Follow
    Please login to follow content.
  • Like

add to folder:

  • My saved (default)
  • Read later
Folders shared with you

Filed under

  • USA
  • Healthcare & Life Sciences
  • Intellectual Property
  • Venable LLP

Tagged with

  • Biopharmaceutical

Popular articles from this firm

  1. The Most Important U.S. Patent Cases of 2019 Thus Far *
  2. Raising Revenue and Trimming Tax: A Nonprofit's Guide to Corporate Sponsorships *
  3. Website Accessibility Claims on the Rise *
  4. NYC Takes Action on the Use of Mechanical Voids *
  5. Mastering Your Body Language and Professional Destiny - Five Tips to Get You Started *

If you would like to learn how Lexology can drive your content marketing strategy forward, please email enquiries@lexology.com.

Powered by Lexology

Featured Video

Thanos Rammos Dr. Jan Phillip Rektorschek
2:01 min

Thanos Rammos, Dr. Jan Phillip Rektorschek

Taylor Wessing

Go AIIP: AI and data processing
Watch now

Related topic hubs

  1. USA
  2. Healthcare & Life Sciences
  3. Intellectual Property

Related USA articles

  1. Follow-On Biologics': Ensuring Continued Innovation In The Biotechnology Industry *
  2. Biosimilar battlegrounds - what is new in biosimilars and where? *
  3. Endocrine disrupting chemicals (EDC) in drinking water *

Related international articles

  1. More news about ‘sufficiency’ under Australian patent law * - Australia
  2. Subsequent entry biologics in Canada: competition vs. exclusivities * - Canada
  3. The Biosimilar Landscape in Canada * - Canada
Chris Heaphy
General Counsel
The Taubman Company
What our clients say

"I enjoy your publication and read it religiously."

Back to Top
  • Terms of use
  • Cookies
  • Disclaimer
  • Privacy policy
  • GDPR Compliance
  • RSS feeds
  • Contact
  • Submissions
  • About
  • Login
  • Register
  • Follow on Twitter
  • Search
Globe Business Media Group

© Copyright 2006 - 2019 Globe Business Media Group